Walmart Partners With Novo Nordisk To Launch US Private-Label Insulin
Company Launches Insulin Aspart And FlexPens As Interchangeable Biosimilars Loom
Walmart, the famous American multinational retailer, has launched what it is billing as the “first and only” private brand analog insulin, under the company’s brand ReliOn, in partnership with Novo Nordisk. The firm is offering ReliOn NovoLog (insulin aspart) vials and FlexPen in its pharmacies immediately.
You may also be interested in...
Uptake is expected to be “rapid” once Humira biosimilars launch in the US, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen. Meanwhile, milestone first approvals for interchangeable and ophthalmic biosimilars show that the US biosimilars market is moving in the right direction, he tells Generics Bulletin in an exclusive Q&A.
Amid continued debate over biosimilar interchangeability in the US, Viatris has said it expects to pick up the first such approvals later this year with the company’s insulin glargine and insulin aspart biosimilar products.
Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”